^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    NTRK1-TP53 fusion

    i
    Other names: TP53, Tumor Protein P53, Cellular Tumor Antigen P53, Phosphoprotein P53, Tumor Protein P53, Antigen NY-CO-13, Transformation-Related Protein 53, Mutant Tumor Protein 53, P53 Tumor Suppressor, Tumor Suppressor P53, Tumor Protein 53, BMFS5, TRP53, BCC7, LFS1, NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1
    Entrez ID:
    7157; 4914
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Systematic Population-based Identification of NTRK Fusion Genes Among Hispanic Patients with Non-Small Cell Lung Cancer (NSCLC) (IASLC-WCLC 2022)
    The frequency of NTRK fusions among Hispanic patients with NSCLC is similar to that previously reported worldwide. Negative results on NGS may be related to pre-analytical factors such as DNA quality. To the best of our knowledge, this is the first study using a systematic population-based identification of NTRK fusion genes in Latin America.
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK positive • NTRK1-TP53 fusion • NTRK expression • NTRK fusion
    |
    Oncomine Focus Assay • VENTANA pan-TRK (EPR17341) Assay